Home > Boards > US Listed > Biotechs > Portola Phramaceuticals (PTLA)

Interesting comment on SA's

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 13
Posts 1,422
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Re... PR Newswire (US) - 6/19/2019 11:05:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:43:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:37:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:34:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:27:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:20:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/17/2019 5:16:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:49:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/5/2019 5:07:23 PM
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire Inc. - 5/28/2019 4:30:00 PM
Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® i... GlobeNewswire Inc. - 5/22/2019 10:45:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 8:38:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 8:07:58 AM
Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/8/2019 8:01:00 AM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), t... GlobeNewswire Inc. - 4/26/2019 2:00:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/25/2019 11:21:27 AM
Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Developm... GlobeNewswire Inc. - 4/24/2019 8:30:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/22/2019 6:03:30 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/22/2019 6:03:24 AM
Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019 GlobeNewswire Inc. - 4/17/2019 4:15:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:45:27 PM
New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust,... GlobeNewswire Inc. - 4/10/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/8/2019 7:04:44 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/1/2019 7:28:43 PM
H2R   Tuesday, 12/04/18 10:46:35 AM
Re: None
Post # of 178 
Interesting comment on SA's

https://seekingalpha.com/news/3414289-portolas-cerdulatinib-continues-show-positive-action-mid-stage-lymphoma-study

Quote:
Fightdoctor

This was a positive study in a drug that may produce something for Portola investors. However, the main reason to be in this stock is for the drug Andexxa, the reversal agent for Eliquis and Xarelto. The drug is approved but the method of producing it, referred to as Gen 1 is inefficient. Portola is only offering this life saving drug to about 160 US hospitals at this time. Investors are awaiting two decisions. The CHMP decision for the European Union is due next week and the FDA approval decision of the Gen 2 method of producing is due by Dec. 31. Portola has stock piled over $300,000,000 of the Gen. 2 drug in anticipation of that approval. The drug is being manufactured by a very reliable Swiss company, Lonza. They have an excellent record of bringing drugs through regulatory processes.

The stock as been beaten down with a very large short interest. That has presented an uncommon opportunity to get in on a company at a low price.
I am a long term believer in Portola and Andexxa. There are lots of opinions as to when this company share price will take off and how high it will go. But, based on the action at the time of previous, less momentous, announcements I am expecting two large pops soon.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist